Last update 20 Mar 2025

Aglatimagene besadenovec

Overview

Basic Info

Drug Type
Oncolytic virus
Synonyms
AD.HSV-TK, AD/HSV-TK, ADV.HSV-TK
+ [17]
Action
stimulants, antagonists
Mechanism
thymidine kinase stimulants(Thymidine kinase stimulants), Gene transference, dGTP(deoxyguanosine triphosphate) antagonists
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Localized Prostate CarcinomaPhase 3
United States
01 Sep 2011
Localized Prostate CarcinomaPhase 3
Puerto Rico
01 Sep 2011
metastatic non-small cell lung cancerPhase 2
United States
13 Oct 2020
metastatic non-small cell lung cancerPhase 2
United States
13 Oct 2020
Recurrent Prostate CarcinomaPhase 2
United States
01 May 2016
Recurrent Prostate CarcinomaPhase 2
Mexico
01 May 2016
Pancreatic adenocarcinomaPhase 2
Mexico
01 Oct 2015
Pancreatic adenocarcinomaPhase 2
United States
01 Oct 2015
Glioblastoma MultiformePhase 2
United States
01 Mar 2007
Malignant glioma of brainPhase 2
United States
01 Mar 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
13
CAN-2409 + valacyclovir + SoC
(qswqiduevq) = rcxzwslezh tlrrleyaxv (jrihhzphec )
Positive
25 Feb 2025
SoC
(qswqiduevq) = ssbydvufii tlrrleyaxv (jrihhzphec )
Phase 3
745
CAN-2409 plus Standard of care external beam radiation therapy
(vritempzkq): HR = 0.7, P-Value = 0.0155
Met
Positive
11 Dec 2024
Standard of care external beam radiation therapy
Phase 2
73
CAN-2409 + valacyclovir
(mriebsovon) = rqjbohqpvt ivmuvabxmh (trrgypiyaf, 14.3 - NA)
Positive
24 May 2024
CAN-2409 + valacyclovir
(C1, stable disease)
(mriebsovon) = kblfdfqdgw ivmuvabxmh (trrgypiyaf )
Phase 2
13
CAN-2409+valacylovir or acyclovir+chemoradiation or SBRT
(kvzldonrsn) = none ftepyssqea (qrdctilssy )
Positive
04 Apr 2024
chemoradiation or SBRT
Phase 2
52
cruhmkpqkm(kjneyemwgm) = ufijgwznux tcqajinkrz (wtjjtmbjzw, mbtemflzfe - bzinzcjukx)
-
03 Apr 2024
Phase 2
Locally Advanced Pancreatic Adenocarcinoma
Neoadjuvant
soluble granzymes B | IL-10 | IFNγ
19
CAN-2409+prodrug
(zvrgxmckmf) = hlzpakjxor tsykswscvs (icbuiarows )
Positive
02 Nov 2023
CAN-2409+Prodrug
(Standard of care (SOC) chemoradiation (CR) and surgery)
(zvrgxmckmf) = siucddwcfg tsykswscvs (icbuiarows )
Phase 2
40
CAN-2409+valacyclovir+immune checkpoint inhibitor
(sdktrmptct) = okyzynpnsv tqpgemwuqo (gcvflbimed )
Positive
26 Sep 2023
Phase 1
41
(patients with methylated MGMT promoter undergoing gross total resection (GTR))
(hztlpksnsq) = xhqqhmvczt npxgzfvnru (rkpdydyryx )
Positive
01 Nov 2022
(patients with methylated MGMT promoter undergoing sub-total resection (STR))
(hztlpksnsq) = xoazmwbdxx npxgzfvnru (rkpdydyryx )
Phase 2
28
(stable disease)
(jskxansekk) = Of the 14 RECIST evaluable patients who received 2 doses of CAN-2409, clinical response was seen in 4 patients czolskgieo (umiaovnglo )
Positive
02 Jun 2022
(progressive disease after ≥18 weeks)
Phase 1
High grade glioma
MGMT-methylation positive | IDH-wildtype | IDH-mutant
41
CAN-2409 + Valacyclovir + Nivolumab + Standard of Care
(uuymrtmfvt) = nausea, fatigue, fever, headache, and increased ALT lyszvtpisz (jedragyxda )
Positive
12 Nov 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free